Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature.

Brent D Van Rite, John J Krais, Mohamad Cherry, Vassilios I Sikavitsas, Carla Kurkjian, Roger G Harrison

Index: Cancer Invest. 31(8) , 505-10, (2013)

Full Text: HTML

Abstract

The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.